Sun Pharma Advanced Research Co. Ltd. (IN:SPARC)
:SPARC
Want to see IN:SPARC full AI Analyst Report?
SPARC Stock Chart & Stats
₹135.70
-₹2.58(-1.32%)
At close: 4:00 PM EST
₹135.70
-₹2.58(-1.32%)
Day’s Range― - ―
52-Week Range₹108.20 - ₹213.80
Previous CloseN/A
Volume383.41K
Average Volume (3M)24.00K
Market Cap
₹58.56B
Enterprise Value₹73.66B
Total Cash (Recent Filing)₹30.00M
Total Debt (Recent Filing)₹4.17B
Price to Earnings (P/E)2.4
Beta1.78
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.23
Shares Outstanding324,521,580
10 Day Avg. Volume27,089
30 Day Avg. Volume24,005
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.78
Price to Sales (P/S)1.98
P/FCF Ratio-12.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scalable Out-licensing ModelSPARC’s business model monetizes R&D via out-licensing, milestones and royalties, which is capital-efficient and scalable. Over months this structure can enable upside from successful candidates without proportionate capex, aligning cash needs with program de-risking and partner execution.
Strong FY2026 Revenue And Profit ReboundA material step-up to 18.79B revenue and a swing to profitability suggests recent programs or deals meaningfully crystallized value. If driven by durable licensing or commercialization milestones, this improves funding optionality and validates development capability for the medium term.
Improved Leverage In FY2026FY2026 leverage appears manageable with debt-to-equity around 0.42 and sizable assets, giving the company greater financial flexibility. This improvement can support continued R&D investment or partnership negotiations and reduces short-term default or covenant pressure.
Bears Say
Chronic Negative Cash FlowPersistent operating and free cash flow deficits, including large negative cash flows in FY2026, indicate the company burns cash despite reported accounting profits. This creates ongoing funding needs, heightens refinancing risk, and undermines earnings quality over the medium term.
Volatile Earnings HistoryA multi-year pattern of losses followed by an extreme one-year profit swing points to earnings volatility and potential one-off drivers. Such instability complicates partner and investor assessment of sustainable margins, making medium-term planning and deal pricing more challenging.
Historic Balance-sheet StrainEpisodes of negative equity and unstable leverage historically signal past financial strain and raise questions about resilience to setbacks. This legacy increases the likelihood of higher cost of capital, more onerous financing terms, and sensitivity to adverse shocks over the coming months.
Sun Pharma Advanced Research Co. Ltd. News
SPARC FAQ
What was Sun Pharma Advanced Research Co. Ltd.’s price range in the past 12 months?
Sun Pharma Advanced Research Co. Ltd. lowest stock price was ₹108.20 and its highest was ₹213.80 in the past 12 months.
What is Sun Pharma Advanced Research Co. Ltd.’s market cap?
Sun Pharma Advanced Research Co. Ltd.’s market cap is ₹58.56B.
When is Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date?
Sun Pharma Advanced Research Co. Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 79 days.
How were Sun Pharma Advanced Research Co. Ltd.’s earnings last quarter?
Sun Pharma Advanced Research Co. Ltd. released its earnings results on May 18, 2026. The company reported ₹54.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹54.27.
Is Sun Pharma Advanced Research Co. Ltd. overvalued?
According to Wall Street analysts Sun Pharma Advanced Research Co. Ltd.’s price is currently Overvalued.
Does Sun Pharma Advanced Research Co. Ltd. pay dividends?
Sun Pharma Advanced Research Co. Ltd. does not currently pay dividends.
What is Sun Pharma Advanced Research Co. Ltd.’s EPS estimate?
Sun Pharma Advanced Research Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sun Pharma Advanced Research Co. Ltd. have?
Sun Pharma Advanced Research Co. Ltd. has 324,521,580 shares outstanding.
What happened to Sun Pharma Advanced Research Co. Ltd.’s price movement after its last earnings report?
Sun Pharma Advanced Research Co. Ltd. reported an EPS of ₹54.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.886%.
Which hedge fund is a major shareholder of Sun Pharma Advanced Research Co. Ltd.?
Currently, no hedge funds are holding shares in IN:SPARC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sun Pharma Advanced Research Co. Ltd.
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited
Technical Analysis
Jubilant Pharmova Limited
―
Neuland Laboratories Ltd.
―
Piramal Pharma Limited
―
Suven Life Sciences Limited
―
Suven Pharmaceuticals Ltd.
―